Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29976707 | 1.00 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2HTR1AAPLNR | |
| SCHEMBL474102 | 0.84 | HTR2A (0.46) | SLC6A4HTR2AKCNH2HTR1AMEN1 | |
| SCHEMBL11530709 | 0.82 | RELA (0.48) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL11530716 | 0.82 | RELA (0.48) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4519124 | 0.82 | KDM4E (0.37) | SLC6A4HTR2AKCNH2HTR1AMEN1 | |
| SCHEMBL4510419 | 0.82 | ALDH1A1 (0.53) | SLC6A4HTR2AKCNH2HTR1AAPLNR | |
| SCHEMBL8340513 | 0.82 | SLC6A4 (0.47) | SLC6A4HTR2AKCNH2HTR1AAPLNR | |
| SCHEMBL2060421 | 0.81 | HTR2A (0.47) | HTR2AAPLNRCA12CA1CA2 | |
| SCHEMBL1391304 | 0.81 | NQO1 (0.46) | MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3719649 | 0.81 | EPHX2 (0.42) | SLC6A4HTR2AHTR1AKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| CN-108602811-B | FXR receptor agonists | 轩竹生物科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| EP-2432776-B1 | METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | UNIV LAVAL (CA) | 2019-09-11 | — | — | EP | disclosed |
| CN-110023292-A | Apoptosis inhibitor | 北京生命科学研究所 | 2019-07-16 | — | — | CN | disclosed |
| WO-1995020572-A1 | 1-H-3-ARYLPYRROLIDINE-2,4-DIONE DERIVATIVES AS PEST-CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-08-03 | — | — | WO | disclosed |
| EP-0253766-B1 | STABILIZED OLEFIN POLYMER INSULATING COMPOSITIONS | CIBA-GEIGY AG (CH) | 1992-03-11 | — | — | EP | disclosed |
| EP-0252878-B1 | VOLTAGE STABILIZED POLYOLEFIN COMPOSITIONS AND SILICONE-GLYCOL DERIVATIVES SUITABLE THEREFOR | CIBA-GEIGY AG (CH) | 1990-11-22 | — | — | EP | disclosed |
| US-4724248-A | POLYDIALKYLSILOXANEPOLYOXYALKYLENE BLOCK AND/OR GRAFT COPOLYMERS | CIBA-GEIGY CORPORATION (US) | 1988-02-09 | — | — | US | disclosed |
| EP-0253766-A2 | Stabilized olefin polymer insulating compositions | CIBA-GEIGY AG (CH) | 1988-01-20 | — | — | EP | disclosed |
| EP-0252878-A1 | Voltage stabilized polyolefin compositions and silicone-glycol derivatives suitable therefor | CIBA-GEIGY AG (CH) | 1988-01-13 | — | — | EP | disclosed |
| US-4689362-A | POLYSILOXANE POLYOXYALKYLENE BLOCK OR GRAFT COPOLYMERS AS STABILIZERS | CIBA-GEIGY CORPORATION (US) | 1987-08-25 | — | — | US | disclosed |
| US-4268678-A | 4-(Arylaliphatic)isoxazoles | STERLING DRUG INC. (US) | 1981-05-19 | — | — | US | disclosed |
| US-4171371-A | Diketones | STERLING DRUG INC. (US) | 1979-10-16 | — | — | US | disclosed |
| US-4153719-A | Aromatic diketones | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | SLC6A4 3822/4885HTR2A 3517/4885KCNH2 3722/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | SLC6A4 1160/4885HTR2A 134/4885KCNH2 1883/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | SLC6A4 3822/4885HTR2A 3517/4885KCNH2 3722/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | SLC6A4 3822/4885HTR2A 3517/4885KCNH2 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.